newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on track to initiate